Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR.
Journal
Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
25
05
2021
accepted:
02
05
2022
pubmed:
14
6
2022
medline:
15
11
2022
entrez:
13
6
2022
Statut:
ppublish
Résumé
Fast, high-throughput methods for measuring the level and duration of protective immune responses to SARS-CoV-2 are needed to anticipate the risk of breakthrough infections. Here we report the development of two quantitative PCR assays for SARS-CoV-2-specific T cell activation. The assays are rapid, internally normalized and probe-based: qTACT requires RNA extraction and dqTACT avoids sample preparation steps. Both assays rely on the quantification of CXCL10 messenger RNA, a chemokine whose expression is strongly correlated with activation of antigen-specific T cells. On restimulation of whole-blood cells with SARS-CoV-2 viral antigens, viral-specific T cells secrete IFN-γ, which stimulates monocytes to produce CXCL10. CXCL10 mRNA can thus serve as a proxy to quantify cellular immunity. Our assays may allow large-scale monitoring of the magnitude and duration of functional T cell immunity to SARS-CoV-2, thus helping to prioritize revaccination strategies in vulnerable populations.
Identifiants
pubmed: 35697804
doi: 10.1038/s41587-022-01347-6
pii: 10.1038/s41587-022-01347-6
pmc: PMC10603792
mid: NIHMS1890582
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1680-1689Subventions
Organisme : NCI NIH HHS
ID : U24 CA224319
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK124165
Pays : United States
Organisme : NCI NIH HHS
ID : K00 CA212474
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA078207
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA196521
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Nature. 1985 Jun 20-26;315(6021):672-6
pubmed: 3925348
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
Med. 2021 Jun 11;2(6):682-688.e4
pubmed: 33851143
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
PLoS Comput Biol. 2020 Feb 25;16(2):e1007664
pubmed: 32097405
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
Vaccine. 2017 Apr 4;35(15):1898-1906
pubmed: 28285985
Lancet. 2021 Jul 10;398(10295):121-130
pubmed: 34181880
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
J Exp Med. 2021 May 3;218(5):
pubmed: 33646265
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Lancet Respir Med. 2021 Nov;9(11):1255-1265
pubmed: 34391547
Clin Infect Dis. 2021 Nov 2;73(9):e3130-e3132
pubmed: 33035306
Nature. 2022 Jan;601(7891):110-117
pubmed: 34758478
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Infect. 2021 Feb;82(2):282-327
pubmed: 32853599
Blood Cancer J. 2021 Aug 10;11(8):142
pubmed: 34376633
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Genome Biol. 2014;15(12):550
pubmed: 25516281
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Nature. 2015 Jul 2;523(7558):96-100
pubmed: 25970242
Nucleic Acids Res. 2021 Jan 8;49(D1):D884-D891
pubmed: 33137190
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Am J Transplant. 2021 Aug;21(8):2727-2739
pubmed: 34036720
Clin Microbiol Infect. 2021 Feb;27(2):286.e7-286.e13
pubmed: 33045370
Nat Immunol. 2022 Jan;23(1):50-61
pubmed: 34853448
Am J Respir Crit Care Med. 2013 Jan 1;187(1):65-77
pubmed: 23144331
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
J Vis Exp. 2021 Sep 17;(175):
pubmed: 34605812
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Clin Infect Dis. 2022 Dec 19;75(12):2079-2087
pubmed: 35521791
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
J Clin Invest. 2021 Sep 1;131(17):
pubmed: 34623327
Lancet. 2021 Mar 27;397(10280):1178-1181
pubmed: 33640037
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Cancer Cell. 2021 Nov 8;39(11):1442-1444
pubmed: 34706273
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228
Cell Rep. 2021 Aug 24;36(8):109570
pubmed: 34390647